Status:
COMPLETED
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients
Lead Sponsor:
Nantes University Hospital
Conditions:
Dementia
Eligibility:
All Genders
45-75 years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to assess the efficacy and tolerability of memantine (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease \[AD\]) in frontotemporal dementia ...
Detailed Description
Background: Frontotemporal dementia (FTD) is the first cause of dementia in the presenium (onset before the age of 65 years). Characterized by behavioral disorders, it is often more incapacitating tha...
Eligibility Criteria
Inclusion
- Patients with FTD based on the criteria defined by the Lund and Manchester groups' consensus statement (revised in 1998), whose disease has been progressing during the last year.
- MMSE score of 19 or higher
- Men and women aged 45 to 75 years
- Without speech, visuospatial, or episodic memory impairments
Exclusion
- Age \> 76 years
- Illiterate or misunderstanding patients
- Patients with cancer, heart disease, lung disease, kidney disease (creatinine \> 200 mg/dL), or epilepsy
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00200538
Start Date
September 1 2005
Last Update
May 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Martine Vercelletto
Nantes, France, 44093